When LXR plays firefighters….
Chronic inflammation is a precursor mechanism supporting cancer development. Regarding the prostate, although hormone deprivation therapy significantly slows down cancer development, it triggers deep alterations in the tumor microenvironment. In its last studi, published in Genome Biology ( Bousset et al.) the NuReP team shows that the absence of nuclear receptors LXR leads to reprogramming of the tumor microenvironment, in particular the immune landscape.
The recruitment of deficient-macrophages in phagocytosis is observed, leading to an aberrant response to the hormone deprivation therapy. This phenotypic alteration leads to the development of prostatic neoplasia. Thus, these data show that hormonal deprivation leads to increase inflammatory background which is intimately linked to the metabolic status of the prostate. Therefore, these findings raise the question of the impact of hormone deprivation therapy in patients with dyslipidemia.
Last modified: 09/14/2021